Introduction. Isoniazid monoresistance is the most common type of single TB drug resistance worldwide. There is no strong evidence regarding the best treatment regime ns in this group of patients. Aim of the study. To assess the impact of HR tuberculosis(TB) on treatment outcomes and survival among pulmonary TB patients treated under TB control program in the Republic of Moldova. Materials and methods. We have performed a comparative retrospective analysis of treatment outcomes in all pulmonary TB patients registered in the National Electronic TB data base (SIME TB) during 2012 2016. Only patients with positive culture and proven isoniazid monoresistance or pan susceptib ility to the first line drugs were included. Results. During 2012 2016, 191 monoresistant and 1889 pan susceptible pulmonary TB cases were registered in SIME TB. No differences in age, gender, previous history of TB and comorbidities between monoresistant and pan susceptible patients have been identified. All study subjects were treated with first line TB drugs regimens recommended by National Treatment Guidelines. Contrary to the expectations no differences were identified between pan susceptible and isoni azid monoresistant subjects regarding the rates of cure(84.2% vs 84.8%, p> 0.05), treatment failure (3.54 vs 5.24%, p> 0.05) and death (6.65% vs 5.76%, p> 0.05). At the same time monoresistant subjects had a shorter treatment duration than those with pan s usceptibility (141 vs 224 days, p < 0.0001) Conclusion. Our findings suggest that compared with pan susceptible TB, patients in with isoniazid monoresistant TB treated under programmatic condition in Republic of Moldova have similar final TB treatment out comes including all cause mortality.